- **TREATMENT CESSATION** Avoid abrupt withdrawal (risk of rebound pulmonary hypertension and pulmonary hypertensive crisis).
- **DIRECTIONS FOR ADMINISTRATION** Directions for administration vary depending on the preparation used—for instructions *in adults*, consult product literature. For *neonatal intensive care*—consult local protocols.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion

- **Veletri** (Actelion Pharmaceuticals UK Ltd)

Epoprostenol (as Epoprostenol sodium) 500 microgram Veletri 500microgram powder for solution for infusion vials | 1 vial PoM £24.44

Epoprostenol (as Epoprostenol sodium) 1.5 mg Veletri 1.5mg powder for solution for infusion vials | 1 vial PoM £49.24

Powder and solvent for solution for infusion

ELECTROLYTES: May contain Sodium

- **Flolan** (GlaxoSmithKline UK Ltd)

Epoprostenol (as Epoprostenol sodium) 500 microgram Flolan 500microgram powder and solvent (pH12) for solution for infusion vials | 1 vial PoM £22.22

Epoprostenol (as Epoprostenol sodium) 1.5 mg Flolan 1.5mg powder and solvent (pH12) for solution for infusion vials | 1 vial PoM £44.76

Iloprost

20-Feb-2019

- **INDICATIONS AND DOSE**

Idiopathic or familial pulmonary arterial hypertension (initiated under specialist supervision)

- BY INHALATION OF NEBULISED SOLUTION
- Child 8-17 years: Initially 2.5 micrograms for 1 dose, increased to 5 micrograms for 1 dose, increased if tolerated to 5 micrograms 6–9 times a day, adjusted according to response; reduced if not tolerated to 2.5 micrograms 6–9 times a day, reduce to lower maintenance dose if high dose not tolerated

Raynaud's syndrome

- BY INTRAVENOUS INFUSION
- Child 12-17 years: Initially 30 nanograms/kg/hour, increased to 60–120 nanograms/kg/hour daily for 3–5 days, dose to be given over 6 hours, dose increase should be performed gradually

- **UNLICENSED USE** Not licensed for use in children.
- **CONTRA-INDICATIONS** Conditions which increase risk of haemorrhage · congenital or acquired valvular defects of the myocardium · decompensated cardiac failure (unless under close medical supervision) · pulmonary veno-occlusive disease · severe arrhythmias · severe coronary heart disease
- **CAUTIONS**

GENERAL CAUTIONS Hypotension (do not initiate if systolic blood pressure below 85 mmHg) · unstable pulmonary hypertension with advanced right heart failure

SPECIFIC CAUTIONS

- When used by inhalation Acute pulmonary infection · severe asthma
- **INTERACTIONS** → Appendix 1: iloprost
- **SIDE-EFFECTS**
- **Common or very common** Chest discomfort · cough · diarrhoea · dizziness · dyspnoea · haemorrhage · headache · hypotension · nausea · oral disorders · pain · palpitations · rash · syncope · tachycardia · throat complaints · vasodilation · vomiting
- **Frequency not known** Respiratory disorders · taste altered · thrombocytopenia

- **PREGNANCY**
- When used by inhalation Use if potential benefit outweighs risk.
- **BREAST FEEDING**
- When used by inhalation Manufacturer advises avoid—no information available.
- **HEPATIC IMPAIRMENT**

Dose adjustments ▸ When used by inhalation Initially 2.5 micrograms at intervals of 3–4 hours (max. 6 times daily), adjusted according to response (consult product literature).

Dose may need to be halved in liver cirrhosis.

- **DIRECTIONS FOR ADMINISTRATION**
- With intravenous use For *intravenous infusion* dilute to a concentration of 200 nanograms/mL with Glucose 5% or Sodium Chloride 0.9%; alternatively, may be diluted to a concentration of 2 micrograms/mL and given via syringe driver.
- When used by inhalation For *inhaled treatment*, to minimise accidental exposure use only with nebulisers listed in *Ventavis*® product literature in a well ventilated room.
- **PRESCRIBING AND DISPENSING INFORMATION**
- When used by inhalation Delivery characteristics of nebuliser devices may vary—only switch devices under medical supervision.
- With intravenous use Concentrate for infusion available on a named patient basis from Bayer Schering in 0.5 mL and 1 mL ampoules.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion

- **Iloprost (Non-proprietary)**

Iloprost (as Iloprost trometamol) 100 microgram per 1 ml Iloprost 100micrograms/1ml solution for infusion ampoules | 1 ampoule PoM Ⓥ

Iloprost 50micrograms/0.5ml solution for infusion ampoules | 1 ampoule PoM Ⓥ

Iloprost 100micrograms/1ml concentrate for solution for infusion ampoules | 1 ampoule PoM £75.00 (Hospital only) | 5 ampoule PoM £300.00 (Hospital only)

Nebuliser liquid

- **Ventavis** (Bayer Plc)

Iloprost (as Iloprost trometamol) 10 microgram per 1 ml Ventavis 10micrograms/ml nebuliser solution 1ml ampoules | 42 ampoule PoM £560.27 | 168 ampoule PoM £2,241.08

Iloprost (as Iloprost trometamol) 20 microgram per 1 ml Ventavis 20micrograms/ml nebuliser solution 1ml ampoules | 42 ampoule PoM £560.27 | 168 ampoule PoM £2,241.08

ENDOTHELIN RECEPTOR ANTAGONISTS

Bosentan

07-Jun-2018

- **INDICATIONS AND DOSE**

Pulmonary arterial hypertension (initiated under specialist supervision)

- BY MOUTH
- Child 2-17 years (body-weight 10-20 kg): Initially 31.25 mg once daily for 4 weeks, then increased to 31.25 mg twice daily
- Child 2-17 years (body-weight 20-40 kg): Initially 31.25 mg twice daily for 4 weeks, then increased to 62.5 mg twice daily
- Child 12-17 years (body-weight 40 kg and above): Initially 62.5 mg twice daily for 4 weeks, then increased to 125 mg twice daily (max. per dose 250 mg)

- **CONTRA-INDICATIONS** Acute porphyrias p. 624
- **CAUTIONS** Not to be initiated if systemic systolic blood pressure is below 85 mmHg
- **INTERACTIONS** → Appendix 1: bosentan